Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Xiuning Le, Tae Min Kim, Herbert H Loong...
https://pubmed.ncbi.nlm.nih.gov/41104928/Actively Recruiting
Led by Bayer · Updated on 2026-10-21
430
Participants Needed
94
Research Sites
134 weeks
Total Duration
Researchers are investigating a new treatment for people with advanced non-small cell lung cancer NSCLC that has spread to nearby tissues or other parts of the body. The focus is on cancers with mutations in the genes that produce the proteins EGFR and HER2, which help cancer cells grow and spread. The study evaluates the safety, best dosage, and how the treatment moves through the body. It also aims to understand how well the treatment works in shrinking or eliminating cancer. The treatment being studied is called sevabertinib BAY2927088, given by mouth as a liquid or tablet once or twice daily in 3-week cycles. The study has four parts dose escalation to find the highest safe dose, backfill to test safe doses in more people, expansion to determine which dose to study further, and extension to assess treatment effectiveness. Participants will continue taking the treatment until their cancer worsens, they experience problems, or they leave the study. Participants will attend up to five visits per cycle where blood and urine samples are taken, scans like CT or MRI are done to check cancer status, and overall health including heart health is monitored. Researchers will track any medical problems or side effects, responses to treatment, and how the drug behaves in the body. The study follows participants for up to several years to monitor safety and treatment effects.
CONDITIONS
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
B
Bayer Clinical Trials Contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Bayer
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | BAY2927088 Oral Dose Escalation and Extension | Standard Systemic Therapy for EGFR/HER2-Mutant Advanced NSCLC |
|---|---|---|
| What it is | BAY2927088 is an investigational oral small molecule designed to target tumors with activating EGFR and/or HER2 mutations in advanced NSCLC. This trial uses multiple formulations in dose escalation and expansion cohorts. | Systemic therapies endorsed by leading guidelines for advanced NSCLC with EGFR or HER2 mutations, including EGFR tyrosine kinase inhibitors for EGFR-mutant disease and HER2-directed regimens for HER2-mutant disease. |
| Role in the trial | Evaluated as a new potential therapy for patients with advanced NSCLC and EGFR/HER2 mutations who have progressed on or are not eligible for standard care. | Serves as the recommended treatment outside clinical trials for similar patients with actionable EGFR or HER2 mutations. |
| Primary use | The trial aims to establish safety, tolerability, pharmacokinetics, initial efficacy, and optimal dosing for BAY2927088 in EGFR/HER2-mutant advanced NSCLC following progression or lack of access to previous standard therapies. | Standard systemic therapies aim to control disease, improve symptoms, and prolong survival in patients with EGFR- or HER2-mutant advanced NSCLC. EGFR TKIs are used in EGFR-mutated cases, HER2-targeted regimens are preferred for HER2-mutated disease. |
| How it is given or performed | Administered orally in dose escalation, expansion, and extension cohorts. Dosing schedule determined by trial stage and pharmacokinetics. | Standard systemic therapies include oral tyrosine kinase inhibitors for EGFR mutations and intravenous or oral HER2-targeted agents for HER2-mutated disease. Treatment schedules and regimens are determined per guidelines. |
| Evidence status | Early clinical evidence for BAY2927088 is emerging from ongoing phase 1/2 studies. Published report (Le X et al., 2025) indicates activity in HER2-mutant NSCLC. Full efficacy, safety, and long-term outcomes are not yet established. | Established therapies for EGFR or HER2-mutant advanced NSCLC are supported by multiple randomized trials, guideline endorsements, and extensive clinical use. Demonstrated efficacy includes improved response rates, progression-free survival, and overall survival compared to chemotherapy for EGFR-mutant disease. |
| Important limitations | As an early-phase investigational therapy, BAY2927088 has limited long-term safety and efficacy data. Optimal patient selection, resistance mechanisms, and best dosing strategy remain under investigation. Safety profile continues to be studied, particularly in expansion cohorts. | Guideline-recommended therapies may eventually fail due to resistance mutations, progressive disease, or treatment intolerance. For HER2-mutant disease, optimal regimens and sequencing remain areas of active research. Access to some HER2-targeted agents may vary regionally. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Varies by participant
Participants receive increasing doses of BAY2927088 to find the highest safe dose, with additional participants testing safe doses concurrently.
Up to 5 visits per 3-week cycle
Duration - Varies by participant
Participants receive BAY2927088 at doses found safe in earlier parts to determine optimal dose for further studies.
Up to 5 visits per 3-week cycle
Duration - Varies by participant
Participants continue BAY2927088 treatment to evaluate effectiveness and safety at the selected dose.
Up to 5 visits per 3-week cycle
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Xiuning Le, Tae Min Kim, Herbert H Loong...
https://pubmed.ncbi.nlm.nih.gov/41104928/Bayer
Lead Sponsor